Stockreport

pSivida Submits New Drug Application (NDA) for Durasert™ Three-Year Treatment for Posterior Segment Uveitis to the U.S. FDA

PSIVIDA  (PSDV) 
Last psivida earnings: 2/7 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.psivida.com
PDF WATERTOWN, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technolog [Read more]